Organizations to combine expertise to further develop AI/ML-powered drug design platform, delivering precise, effective, and life-changing medicines at scale
Data to establish the safety profile and human dose of vaccine candidate
New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
According to statistics, the global inhalation drug market reached US $ 25 billion in 2020
Subscribe To Our Newsletter & Stay Updated
